Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dTwuCfbwoceNjNiNBCkt

October 5, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
Get It Right: Pricing Strategies That Work
Many entrepreneurs hope for success by offering low prices, while in fact most world-class entrepreneurs succeed by setting higher prices. If you're not exactly sure which pricing strategy will work for your business, these 6 steps can help you set your company's prices for success. Read the exclusive article now.

  Health Care & Policy 
 
  • Panel suggests ways to avoid clinical trial data gaps
    Gaps in clinical trial data can undermine the trials' credibility and are often due to patients' failure to continue compliance because the treatment does not work, causes side effects or is inconvenient, experts say. An expert panel of the National Research Council suggests continuing to follow up on such patients, briefly testing all patients' tolerance for the active drug at the trial's beginning, permitting the use of rescue medications, cutting the length of follow-up periods and targeting groups that do not have many treatment options. HealthDay News (10/3) LinkedInFacebookTwitterEmail this Story
  • Startup nPharmakon turns drug development upside down
    Biotech firm nPharmakon has developed a platform that analyzes molecules for their effect on diseases, rather than identifying a specific disease target. The program retargets molecules whose safety has been proven but which have not proved effective against the target disease. nPharmakon works with drugmakers and has found new targets for about 12 drugs. MedCityNews.com (10/3) LinkedInFacebookTwitterEmail this Story
Combating Identity Theft in a Mobile, Social World
Mobile connectivity threats extend from consumers to the business environment. But who is really responsible for securing sensitive information? Smart business leaders are becoming proactive on the matter. Learn how to get protected in this white paper. Download the white paper now.

  Company & Financial News 
  • Study finds ways to make biomedical investing more secure
    Biomedical firms can use financial techniques such as securitization to raise more-patient capital and increase financial security, researchers report in Nature Biotechnology. The idea is to create megafunds of $5 billion to $15 billion that issue debt and equity securities, and use the proceeds to invest in a vast portfolio of biomedical research projects. Reuters/Felix Salmon blog (10/1), Nature (9/30) LinkedInFacebookTwitterEmail this Story
  • Funding round pulls in $1 million for Pa. maker of ADHD test
    BioBehavioral Diagnostics, maker of an FDA-approved test for attention-deficit/hyperactivity disorder, has obtained $1 million in its latest financing round. The funding comes as the Plymouth Meeting, Pa.-based company works to extend reach of its diagnostic device in the U.S. and seek CE mark approval in Europe. MedCityNews.com (10/3) LinkedInFacebookTwitterEmail this Story
  • NIH awards Colby a grant to develop prostate cancer drugs
    Colby Pharmaceutical won a Small Business Innovation Research grant from the National Cancer Institute to develop small-molecule novel therapeutics for prostate cancer. The drugs are designed to inhibit interaction between JunD protein and androgen receptor protein. "With this ... award and the recent merger with Othera Pharmaceuticals, Colby is adding to its pipeline of promising ... cancer drug candidates and products for potential partnering," CEO David Zarling said. Pharmaceutical Business Review Online (10/3) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  • L.A. Times: Vote no on Calif. biotech labeling law
    California voters should reject the Proposition 37 biotech labeling law, according to the Los Angeles Times. Not only is there no legitimate reason to single out biotech products, but Prop 37 is overly restrictive, sloppily written and burdensome for retailers, according to this editorial. Los Angeles Times (tiered subscription model) (10/4) LinkedInFacebookTwitterEmail this Story
 
  Industrial & Environmental 
  • Drought-resistant elephant grass could be a cellulosic feedstock
    Two Department of Agriculture agencies are working on making elephant grass a feedstock for cellulosic ethanol. The Agricultural Research Service and the U.S. Forest Service are searching for new biomass crops. Elephant grass is drought-resistant and will not seed if there is a frost over the winter, which makes it less likely to be invasive in areas where it is grown, said William Anderson, a research geneticist at the ARS Crop Genetics and Breeding Research Unit. EthanolProducer.com (10/3) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
The lure of the distant and the difficult is deceptive. The great opportunity is where you are."
--John Burroughs,
American naturalist and essayist


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information